Truist initiated coverage of Nuvalent (NUVL) with a Buy rating and $140 price target Nuvalent is emerging as a disruptive precision oncology company poised for commercial transformation by 2026 with two lead candidates approaching potential approval in oncogene-driven non-small cell lung cancer, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL: